TORC stock forecast
Our latest prediction for resTORbio, Inc.'s stock price was made on the Dec. 18, 2019 when the stock price was at 1.18$.
In the short term (2weeks), TORC's stock price should underperform the market by -5.36%. During that period the price should oscillate between -16.87% and +25.24%.
In the medium term (3months), TORC's stock price should underperform the market by -12.70%. During that period the price should oscillate between -43.29% and +50.85%.Get email alerts
Create a solid portfolio with TORC
About resTORbio, Inc.
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.70$ per share.
The book value per share is 4.18$
Three months stock forecastDec. 18, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|